A filter-flow perspective of hematogenous metastasis offers a
  non-genetic paradigm for personalized cancer therapy by Scott, Jacob G. et al.
A filter-flow perspective of hematogenous metastasis offers a
non-genetic paradigm for personalized cancer therapy
Jacob G. Scott1,2, Alexander G. Fletcher2, Philip K. Maini2, Alexander R.A. Anderson1, & Philip
Gerlee1,3
1 Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center and Research Institute,
Tampa, FL, USA
2 Wolfson Centre for Mathematical Biology, Mathematical Institute, Radcliffe Observatory
Quarter, Oxford University, Woodstock Road, Oxford OX2 6GG, UK
3 Mathematical Sciences, University of Gothenburg and Chalmers University of Technology,
SE-41296 Gothenburg, Sweden
Prepublication draft.
Running title: filter-flow perspective
Keywords: metastasis, mathematical model, cancer, personalized medicine, oligometastasi
Correspondence:
Jacob G. Scott, jacob.g.scott@gmail.com and Philip Gerlee, gerlee@chalmers.se
1
ar
X
iv
:1
30
9.
50
78
v1
  [
q-
bio
.T
O]
  1
9 S
ep
 20
13
Abstract
Research into mechanisms of hematogenous metastasis has largely become genetic in focus, at-
tempting to understand the molecular basis of ‘seed-soil’ relationships. Preceeding this biological
mechanism is the physical process of dissemination of circulating tumour cells (CTCs). We utilize
a ‘filter-flow’ paradigm to show that assumptions about CTC dynamics strongly affect metastatic
efficiency: without data on CTC dynamics, any attempt to predict metastatic spread in individual
patients is impossible.
Brief Communication
Nearly 150 years after Ashworth’s discovery of the vector of hematogenous metastatic disease, the
circulating tumor cell (CTC) Ashworth [1869], the mechanisms driving this process remain poorly
understood and unstoppable Plaks et al. [2013].For over a century the dominant paradigm has
been the seminal, yet qualitative, seed-soil hypothesis proposed by Paget in 1889 Paget [1989].
This began to be challenged in 1992, when a quantification of the contribution of mechanical and
seed-soil effects was attempted by Weiss [Rapp, 2001], who considered the ‘metastatic efficiency
index’ (MEI) of individual primary tumors and metastatic sites Weiss [1992]. He calculated MEI as
the ratio of metastatic involvement to blood flow through an organ and three classes emerged: low,
where the soil-organ relationship is hostile; high, where it is friendly; and medium, where blood flow
patterns to a large extent explain patterns of spread. The utility of Weiss’ classification method
largely ended there, and has since been put aside in favor of genetic correlations Minn et al. [2005],
Bos et al. [2009]. While illuminating, this approach has yet to offer any actionable conclusions,
and its applicability is threatened by the growing understanding that genetic heterogeneity, not
clonality, is the rule in cancer Marusyk et al. [2012], Gerlinger et al. [2012].
We seek here to use Weiss’ MEI and a recently proposed model of CTC dynamics (summarised
in Figure 1) Scott et al. [2012, 2013] to extend our understanding of metastasis. In so doing, we can
explain, using a translatable, patient parameter-specific method, the population-level data for any
given cancer. Our method also presents a way to utilize ‘personalized’ patient CTC measurements
to assay for the burden and distribution of metastatic disease which can be used for guiding organ-
directed therapy and more precise staging.
Until recently, even perfect information about the existence and distribution of metastatic dis-
ease would have done little to affect treatment choice, as the options were largely limited to the
use of systemic chemotherapy. However, recent years have witnessed the advent of more effective
localized therapies for metastatic involvement, in the form of liver-directed therapy, bone-seeking
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radionuclides and stereotactic body radiation therapy. These novel modalities have allowed for tar-
geted therapy to specific parts of the body with minimal side efffects and high eradication potential.
Further, trials offering treatment with curative intent to patients with limited, ‘oligometastatic’ dis-
ease have shown promise Milano et al. [2009, 2012], although it is not yet possible to identify such
patients in an objective manner Weichselbaum and Hellman [2011].
Figure 1: Schematic of the human vascular system network topology. It is evident by inspection
of the network diagram that tumors originating in the gut and lung experience significantly differ-
ent flow patterns and a different order in which they experience filtration at capillary beds than
tumors originating in other parts of the ‘body’ [Scott et al., 2012]. The alternate pathways (green)
represent the fraction of cells which evade arrest (filtration) at a given capillary bed. There are
scant measurements of this fraction in the literature, and none in clinical studies that evaluate
outcomes. We postulate that by ascertaining the distribution of CTCs in this network for indi-
vidual patients, information about the existence of subclinical metastatic disease, and therefore
metastatic propensity, will come to light, and allow for better staging, prognostication and rational
use of organ-directed therapy in the setting of oligometastatic disease.
In this letter we extend Weiss’ method to understand metastatic proclivities of certain organ
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sites and to provide a framework by which to understand the metastatic distribution from novel
CTC measurements. To do this, we consider blood flow between organs Williams and Leggett [1989],
filtration in capillary beds (see Figure 1 and Table 1) and distribution of metastatic involvement in
a series of untreated patients at autopsy Disibio and French [2008]. For each organ-organ pair we
calculate the MEI by normalising incidence by putative CTC flow between the two organs, taking
into account the reduction that occurs in capillary beds Scott et al. [2012, 2013]; which has been
shown to be of the order of 10−4 cell−1 Okumura et al. [2009]. This post-capillary bed reduction in
CTC numbers can be altered by the presence of micrometastases, which can amplify CTC numbers
downstream of their location through shedding. Thus, by adjusting filtration rates throughout
the network, we can represent any different configuration of metastatic disease and thus capture
different organ-organ metastatic efficiencies.
To illustrate the effect of micrometastatic disease on MEIs, we compare four scenarios for a set
of representative organ pairs: no micrometastases, micrometastases present in the lung, in the liver
and in both locations (Figure 2). We see that Weiss’ metric differs from ours, but more importantly
that the metastatic efficiency depends on the current disease state. For example, our estimate of the
efficiency with which cells orginating from a primary pancreatic tumor can form kidney metastases
varies over six orders of magnitude, depending on whether micrometastatic lesions are present, and
their location. This effect highlights an opportunity to go a step further in disease characterization
than presence or absence of CTCs at staging.
The preceding analysis assumes that the filtration rate for each organ is identical for all patients
in the data set. This is likely a gross oversimplification, but no clinical trial has yet determined the
intrapatient heterogeneity in this (currently absent) parameter set. Previously we used incidence
data to calculate MEIs, but we may also reverse the process and calculate the prevalence of mi-
crometastatic disease given incidence data and organ-pair MEIs. Under this reasoning it is possible
to show, for example, that the population incidence of metastases in the adrenal gland arising from
primaries in the large intestine, which equals 7.5%, can be explained not only by a single patient
group composition, but by a whole collection (see online methods). Indeed, the same argument can
be made for any primary-metastasis pair: the population-level data tell us nothing about a given
patient.
To enable these insights and their translation to the clinic, systematic testing of individual
patient filter-flow parameters is required. Measurement of CTCs at initial staging and subsequent
correlation with outcomes would yield initial model parameters with which rational prospective
trials could be designed. This level of understanding of an individual patient’s disease state consti-
tutes a new type of personalized medicine, which seeks to assay not just the collection of mutations
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Figure 2: The impact of filter and flow characteristics on estimation of the metastatic efficienct
index (MEI). We have compared Weiss’ original method with our filter-flow framework under the
assumption of no micrometastases, micrometastases in the lung, in the liver, and in both locations.
The comparison is carried out for four organ pairs that cover the canonical pathways of spread (gut
→ body, body → body, lung → body and body → liver). We see that because Weiss’ method only
considers the dynamics on the arterial side it underestimates the MEI in two of the cases (pancreas
→ kidney, and bladder → liver). From the comparison it is also evident that assumptions about
the presence or absence of micrometastases heavily influences the results, in the case of pancreas
→ kidney shifting the MEI six orders of magnitude from a low MEI to a high one (as defined by
Weiss Weiss [1992]).
that a patient’s cancer cells have accumulated, but instead their physical location. This would allow
for more accurate staging and the rational inclusion of organ directed therapy in clinical trials, a
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concept which is gaining popularity with recently approved methods existing for bone and liver
[Harrison et al., 2013, Seront and Van den Eynde, 2012].
By further elucidating the principles underlying hematogeonous metastasis, we hope to make
inroads toward therapeutic strategy changes that would otherwise be impossible. Our results
highlight the value of the physical perspective of the metastatic cascade, and the importance of
addressing not only genetic factors, but also physiological and anatomical aspects of the process,
which in this gene-centric era have been largely forgotten.
Online methods
Calculation of Metastatic Efficiency Index (MEI)
The autopsy dataset used in the analysis covers 3827 patients presenting with primary tumors
in 30 different anatomical sites Disibio and French [2008]. For each primary tumor the number of
metastases are reported according to anatomical site (in total 9484 metastases). As we focus on the
effect of blood flow patterns, we consider only the organs for which blood flow has been measured,
and this reduces the number of anatomical sites to 14 (detailed in Table 2).
For each organ-organ pair we calculate the metastatic involvement Nij as the ratio between the
number of occurrences of the primary tumor in organ i and the number of metastases reported in
the target organ j, for each pair (i, j) presented in the autopsy data Disibio and French [2008].
We have that 0 ≤ Nij < 1 and this number corresponds to the fraction of cases where a primary
tumor in organ i gave rise to a metastasis in organ j. The metastatic efficiency index (MEI) from
organ i to j is then defined by Mij = Nij/φij , where φij is the relative flow of CTCs from organ
i to j. This quantity takes into account the blood flow that each target organ receives (Table 1)
and the reduction in CTCs that occurs en route between the two organs. For the sake of simplicity
we consider only the effects of capillary bed passage, and it has been shown in clinical studies that
approximately 1 in 10 000 CTCs remain viable after such a passage Okumura et al. [2009]. We thus
assume that there occurs a reduction of CTC number by a factor Fk when the cells pass through
organ k. As a baseline, we use the pass rate Fk = 10
−4 for all organs.
It is well known that metastases in the lung and liver have the ability to shed cells into the
bloodstream and hence give rise to ‘second order’ metastases Bross et al. [1975]. If one were to
measure the CTC concentration downstream of an organ containing metastases, then it would be
higher than in the case of a disease-free organ. For our purposes, this implies that the presence of
metastatic disease can be represented in the model as a lower reduction of CTCs in the capillary
bed of the affected organ. This simplification is only valid if we disregard the biological properties of
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the CTCs (since CTCs originating from metastases might have different genotypes and phenotypes
compared to cells from the primary tumor), but is sufficient for our purposes. To simulate the
presence of micrometastases in the lung and liver we therefore change the pass rates to FL = 10
−1
and FH = 10
−1 respectively.
As an example of our methodology, we now present the calculations for the MEI for breast to
adrenal gland. The cancer cells leaving a breast tumor enter the circulation on the venous side
and are transported via the heart to the lung capillary bed, through which only a fraction FL pass
as viable cells. These cells then flow into the arterial side of the circulation and are randomly
distributed to the different organs of the body according to blood flow, of which the adrenal gland
receives 0.3% (Table 1). The relative flow of CTCs from breast to adrenal gland is therefore given
by φbreast,adrenal = FL × 0.3 = 0.3× 10−3.
Patient group decomposition
Although we calculated several distinct values of MEIs depending on the pattern of metastatic
spread (presence of micrometastases), it is likely that most tumors originating in the same organ
have roughly the same MEI, and that the presence of metastases in the liver and lung instead affect
the incidence of secondary metastases. We now show how this can be used as a means to suggest
possible patient group decompositions.
The incidence, Nij , relative flow of CTCs, φij and the MEI, Mij are related according to Mij =
Nij/φij , or equivalently φij = Nij/Mij . We now assume that φij is not equal for all patients, and
consider four patient groups: no micrometastases, micrometastases in the lung, micrometastases
in the liver and micrometastases in both. If we now let nk denote the fraction of patients in each
group, k, where
∑
nk = 1, then we can write
4∑
k=1
nkφ
k
ij = Mij/Nij , (1)
where φkij is the flow of CTCs in the different patient groups. This problem is underdetermined,
and the solution (in terms of the fractions ni) is given by any point on a surface defined by (1),
such that ni > 0 for all patient groups and
∑
i ni = 1. This implies that aggregated incidence data
can be explained by many different patient group compositions, each with its distinct pattern of
metastatic progression.
The population incidence of metastases in the adrenal gland arising from primaries in the large
intestine equals 7.5 %, and by fixing the MEI and using the above method, the incidence rate can
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be explained by a subdivision according to 25 % in the no metastasis group, 20 % in the liver
metastases group, 5 % in the lung metastases group, and 50% of the patients harboring metastases
in both liver and lung. However the incidence can also be explained by a subdivision of 5%, 25%,
20% and 50 % into each patient group respectively. This highlights the fact that population-based
measures of incidence cannot be used to predict individual patient metastasis dynamics as different
patients can exhibit fundamentally different patterns of spread.
Table 1: The relative blood flow for the organs considered, taken from Williams and Leggett [1989].
The model compartment refers to the anatomical location of the organs and their relation to the
circulatory system is shown in fig. 1.
Tumor Relative blood flow (%) Model compartment
Liver 6.5 (arterial) + 19 (portal) H
Lung 100 L
Adrenal 0.3 B
Bladder 0.06 B
Bone 5.0 B
Breast 1.0 B
Large intestine 4.0 G
Kidney 19.0 B
Pancreas 1.0 B
Skin 5.0 B
Small intestine 10.0 G
Stomach 1.0 G
Testes 0.05 B
Thyroid 1.5 B
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Table 2: Distribution of metastases according to primary site. Data taken from Disibio and French
[2008].
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Liver 36 0 16 7 0 3 0 1 0 4 1 1 0 1 1
Lung 136 58 48 59 1 38 0 9 30 23 8 6 5 0 15
Adrenal 6 3 2 1 0 3 0 1 1 1 3 0 1 0 1
Bladder 183 25 30 11 0 20 0 1 9 2 1 4 0 0 1
Bone 35 6 18 4 1 15 0 1 2 3 6 0 0 0 0
Breast 432 218 247 149 17 213 54 11 40 49 124 12 17 0 35
Large intestine 560 155 101 42 10 29 0 8 20 13 9 6 1 0 8
Kidney 62 21 30 18 2 20 1 5 8 9 3 4 2 0 1
Pancreas 109 63 29 12 2 7 1 4 8 0 3 6 4 1 3
Skin 161 28 47 25 2 25 3 3 18 14 22 11 5 2 14
Small intestine 19 8 3 0 0 0 0 2 0 0 0 1 1 0 0
Stomach 477 146 84 45 7 39 2 13 14 44 11 25 3 0 5
Testes 25 19 18 6 0 8 0 2 11 3 2 3 2 1 2
Thyroid 43 10 22 4 0 6 0 0 1 3 4 1 0 0 0
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